CA2563051A1 - Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications - Google Patents

Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications Download PDF

Info

Publication number
CA2563051A1
CA2563051A1 CA002563051A CA2563051A CA2563051A1 CA 2563051 A1 CA2563051 A1 CA 2563051A1 CA 002563051 A CA002563051 A CA 002563051A CA 2563051 A CA2563051 A CA 2563051A CA 2563051 A1 CA2563051 A1 CA 2563051A1
Authority
CA
Canada
Prior art keywords
substituted
compound
amount
beta
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002563051A
Other languages
English (en)
French (fr)
Inventor
Teddy Kosoglou
Harry R. Davis
Gilles Jean Bernard Picard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26950511&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2563051(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of CA2563051A1 publication Critical patent/CA2563051A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/02Halogenated hydrocarbons
    • A61K31/025Halogenated hydrocarbons carbocyclic
    • A61K31/03Halogenated hydrocarbons carbocyclic aromatic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05Phenols
    • A61K31/055Phenols the aromatic ring being substituted by halogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002563051A 2001-01-26 2002-01-25 Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications Abandoned CA2563051A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US26439601P 2001-01-26 2001-01-26
US60/264,396 2001-01-26
US32383901P 2001-09-21 2001-09-21
US60/323,839 2001-09-21
CA002434682A CA2434682C (en) 2001-01-26 2002-01-25 Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA002434682A Division CA2434682C (en) 2001-01-26 2002-01-25 Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications

Publications (1)

Publication Number Publication Date
CA2563051A1 true CA2563051A1 (en) 2002-08-01

Family

ID=26950511

Family Applications (3)

Application Number Title Priority Date Filing Date
CA002563051A Abandoned CA2563051A1 (en) 2001-01-26 2002-01-25 Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
CA2562982A Expired - Fee Related CA2562982C (en) 2001-01-26 2002-01-25 Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
CA002434682A Expired - Lifetime CA2434682C (en) 2001-01-26 2002-01-25 Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications

Family Applications After (2)

Application Number Title Priority Date Filing Date
CA2562982A Expired - Fee Related CA2562982C (en) 2001-01-26 2002-01-25 Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
CA002434682A Expired - Lifetime CA2434682C (en) 2001-01-26 2002-01-25 Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications

Country Status (32)

Country Link
US (5) US20020151536A1 (enExample)
EP (2) EP1353696B1 (enExample)
JP (4) JP4777602B2 (enExample)
KR (1) KR100596257B1 (enExample)
CN (1) CN100509058C (enExample)
AR (2) AR033855A1 (enExample)
AT (2) ATE374641T1 (enExample)
AU (1) AU2002247019C1 (enExample)
BR (1) BR0206654A (enExample)
CA (3) CA2563051A1 (enExample)
CL (1) CL2004001174A1 (enExample)
CY (2) CY1108000T1 (enExample)
CZ (2) CZ309209B6 (enExample)
DE (2) DE60216890T2 (enExample)
DK (2) DK1353696T3 (enExample)
EC (1) ECSP11004702A (enExample)
ES (2) ES2274013T3 (enExample)
HU (2) HU230253B1 (enExample)
IL (3) IL156445A0 (enExample)
ME (1) MEP27808A (enExample)
MX (1) MXPA03006725A (enExample)
NO (1) NO331512B1 (enExample)
NZ (1) NZ525921A (enExample)
PL (1) PL208110B1 (enExample)
PT (2) PT1413331E (enExample)
RS (2) RS51449B (enExample)
RU (1) RU2356550C2 (enExample)
SI (2) SI1413331T1 (enExample)
SK (2) SK288217B6 (enExample)
TW (1) TWI337083B (enExample)
WO (1) WO2002058732A2 (enExample)
ZA (1) ZA200305693B (enExample)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
DK1363668T3 (da) * 2001-01-26 2007-11-05 Schering Corp Kombinationer af galdesyrekompleksdanner(e) og sterolabsorptionsinhibitor(er) og behandling af vaskulære indikationer
SI1413331T1 (sl) 2001-01-26 2008-02-29 Schering Corp Kombinacije fenofibrata peroksisomskega proliferator aktivirajocega receptorja (PPAR) z ezetimib zaviralcem absorpcije sterola za vaskularne indikacije
NZ526532A (en) 2001-01-26 2005-01-28 Schering Corp The use of substituted azetidinone compounds for the treatment of sitosterolemia
AR034204A1 (es) * 2001-01-26 2004-02-04 Schering Corp Composiciones y combinaciones de acido nicotinico y derivados del mismo con inhibidor(es) de la absorcion de los esteroles, y el uso de los mismos para preparar medicamentos para el tratamiento para indicaciones vasculares
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
WO2003026643A2 (en) 2001-09-21 2003-04-03 Schering Corporation Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
JP2005512516A (ja) 2001-09-24 2005-05-12 メルク エンド カムパニー インコーポレーテッド スタチン薬物の組合せのスクリーニング方法および選択方法
GB0215579D0 (en) 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
US7135556B2 (en) * 2002-07-19 2006-11-14 Schering Corporation NPC1L1 (NPC3) and methods of use thereof
AR040588A1 (es) 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
AU2003270909A1 (en) * 2002-09-27 2004-04-19 Martek Biosciences Corporation Prophylactic docosahexaenoic acid therapy for patients with subclinical inflammation
CA2504878A1 (en) 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorption inhibitors for the treatment of demyelination
CN100339078C (zh) * 2002-12-16 2007-09-26 橘生药品工业株式会社 固体口服剂型药物
WO2004069193A2 (en) * 2003-02-03 2004-08-19 Thomas Jefferson University Methods and compositions for inhibiting cholesterol uptake
CN1756756A (zh) 2003-03-07 2006-04-05 先灵公司 取代的2-吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7192944B2 (en) 2003-03-07 2007-03-20 Schering Corp. Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
EP1601668B1 (en) 2003-03-07 2008-08-27 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
JP2005015434A (ja) * 2003-06-27 2005-01-20 Kotobuki Seiyaku Kk 血清コレステロール低下剤或はアテローム性硬化症の予防又は治療剤
WO2005046797A2 (en) * 2003-11-05 2005-05-26 Schering Corporation Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
ATE428411T1 (de) * 2003-11-07 2009-05-15 Jj Pharma Inc Hdl-verstärkende kombinationstherapie-komplexe
WO2005061452A1 (en) 2003-12-23 2005-07-07 Astrazeneca Ab Diphenylazetidinone derivates possessing cholesterol absorption inhibitory activity
CA2553769C (en) * 2004-01-16 2011-01-04 Merck & Co., Inc. Npc1l1 (npc3) and methods of identifying ligands thereof
US20070116645A1 (en) * 2004-02-03 2007-05-24 Steven Farber Methods and compositions for inhibiting cholesterol uptake
ATE493973T1 (de) 2004-06-04 2011-01-15 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
US7803838B2 (en) 2004-06-04 2010-09-28 Forest Laboratories Holdings Limited Compositions comprising nebivolol
US7838552B2 (en) 2004-06-04 2010-11-23 Forest Laboratories Holdings Limited Compositions comprising nebivolol
CN1759834B (zh) * 2004-09-17 2010-06-23 中国医学科学院医药生物技术研究所 黄连素或其与辛伐他汀联合在制备用于预防或治疗与血脂有关疾病或症状的产品中用途
US7524831B2 (en) 2005-03-02 2009-04-28 Schering Corporation Treatments for Flaviviridae virus infection
UY29607A1 (es) 2005-06-20 2007-01-31 Astrazeneca Ab Compuestos quimicos
MY148538A (en) 2005-06-22 2013-04-30 Astrazeneca Ab Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
SA06270191B1 (ar) 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
EP1741427A1 (en) * 2005-07-06 2007-01-10 KRKA, D.D., Novo Mesto Pharmaceutical composition comprising simvastatin and ezetimibe
EP1919468A4 (en) * 2005-07-18 2010-02-10 Reliant Pharmaceuticals Inc TREATMENT WITH CHOLESTEROL ABSORPTION INHIBITORS BASED ON AZETIDINONE AND OMEGA-3 FATTY ACID AND COMBINATION PRODUCT THEREOF
WO2007100807A2 (en) 2006-02-24 2007-09-07 Schering Corporation Npc1l1 orthologues
AR060623A1 (es) 2006-04-27 2008-07-02 Astrazeneca Ab Compuestos derivados de 2-azetidinona y un metodo de preparacion
US20070275052A1 (en) * 2006-05-24 2007-11-29 Glenmark Pharmaceuticals Limited Pharmaceutical compositions containing sterol inhibitors
US20070299017A1 (en) * 2006-06-23 2007-12-27 Kanter Mitchell M Compositions for lowering blood serum cholesterol and use in foods, beverages, and health supplements
US20080033019A1 (en) * 2006-08-07 2008-02-07 Duke University Cholesterol lowering drug combination
US20080085315A1 (en) * 2006-10-10 2008-04-10 John Alfred Doney Amorphous ezetimibe and the production thereof
EP2431043A1 (en) * 2007-05-23 2012-03-21 Amcol International Corporation Cholesterol-interacting layered phyllosilicates for suppressing gastrointestinal cholesterol absorption
US8858994B2 (en) 2007-12-10 2014-10-14 Ratiopharm Gmbh Pharmaceutical formulation comprising ezetimibe
EP2168573A1 (en) 2008-09-30 2010-03-31 LEK Pharmaceuticals D.D. Formulations comprising ezetimibe
CN102333528B (zh) * 2009-01-26 2013-12-18 台北医学大学 蕨素化合物用于治疗糖尿病及肥胖之用途
EP2229938B9 (en) 2009-03-13 2012-04-25 Sanovel Ilac Sanayi ve Ticaret A.S. Ezetimibe compositions
WO2010113175A2 (en) 2009-04-01 2010-10-07 Matrix Laboratories Ltd Enzymatic process for the preparation of (s)-5-(4-fluoro-phenyl)-5-hydroxy- 1morpholin-4-yl-pentan-1-one, an intermediate of ezetimibe and further conversion to ezetimibe
TR200904500A2 (tr) 2009-06-10 2009-10-21 Öner Levent Ezetimib nanokristallerinin hazırlanması için yöntem ve farmasötik formülasyonları.
MX357446B (es) 2012-09-27 2018-07-10 Kowa Co Agente terapeutico para dislipidemia.
KR20150079373A (ko) 2013-12-30 2015-07-08 한미약품 주식회사 에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제
CN104337785A (zh) * 2014-11-04 2015-02-11 万全万特制药江苏有限公司 一种含有依折麦布的口腔崩解片及其制备方法
CN105213340A (zh) * 2015-10-29 2016-01-06 无锡福祈制药有限公司 一种依折麦布片及其制备方法
JP2017210455A (ja) * 2016-05-27 2017-11-30 ニプロ株式会社 エゼチミブ含有医薬組成物
CN106310173A (zh) * 2016-08-24 2017-01-11 厦门三川利生物科技有限公司 含过氧化物酶体增殖物激活受体多维果酸醇及其制备方法
US20180338922A1 (en) 2017-05-26 2018-11-29 Esperion Therapeutics, Inc. Fixed dose formulations
EP3437636A1 (en) 2017-08-02 2019-02-06 Adamed sp. z o.o. Pharmaceutical composition comprising ezetimibe
CN109718215A (zh) * 2017-10-30 2019-05-07 海南皇隆制药股份有限公司 一种依折麦布片
KR101983298B1 (ko) * 2018-06-11 2019-05-29 연세대학교 산학협력단 인플라마좀 매개 염증성 질환의 예방 또는 치료용 약학 조성물

Family Cites Families (447)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3108097A (en) * 1963-10-22 Ehnojs
US2809194A (en) * 1957-10-08 Thiadiazine type natriuretic agents
US1286A (en) * 1839-08-13 Richard else
FR1103113A (fr) 1954-04-15 1955-10-31 Triméthylol-alcanes et leur procédé de préparation
FR1217929A (fr) 1958-03-03 1960-05-06 Ciba Geigy Procédé de préparation du 1,1-dioxyde de la 6-chloro-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine et de ses sels
BE578515A (enExample) * 1958-05-07
DE1302648B (enExample) 1960-09-27
NL127065C (enExample) * 1964-04-22
NL137318C (enExample) * 1964-06-09
GB1415295A (en) 1971-10-14 1975-11-26 Orchimed Sa Substituted phenoxy-alkyl-carboxylic acids and derivatives thereof
US3716583A (en) * 1969-04-16 1973-02-13 Sumitomo Chemical Co Phenoxy carboxylic acid derivative
US3692895A (en) * 1970-09-08 1972-09-19 Norman A Nelson Method of reducing hypercholesteremia in humans employing a copolymer of polyethylenepolyamine and a bifunctional substance, such as epichlorohydria
DE2230383C3 (de) * 1971-10-01 1981-12-03 Boehringer Mannheim Gmbh, 6800 Mannheim Phenoxyalkylcarbonsäurederivate und Verfahren zur Herstellung derselben
US4148923A (en) * 1972-05-31 1979-04-10 Synthelabo 1-(3'-Trifluoromethylthiophenyl)-2-ethylaminopropane pharmaceutical composition and method for treating obesity
US3948973A (en) * 1972-08-29 1976-04-06 Sterling Drug Inc. Halocyclopropyl substituted phenoxyalkanoic acids
US4626549A (en) * 1974-01-10 1986-12-02 Eli Lilly And Company Treatment of obesity with aryloxyphenylpropylamines
US4235896A (en) * 1975-02-12 1980-11-25 Orchimed S.A. Benzyl-phenoxy acid esters and hyperlipaemia compositions containing the same
US4179515A (en) * 1975-02-12 1979-12-18 Orchimed S. A. Benzoylphenoxy propionic acid, esters thereof and pharmaceutical composition
JPS5195049A (en) * 1975-02-12 1976-08-20 * **********so*****no***tsu*****************************************ni*no
US4075000A (en) * 1975-05-27 1978-02-21 Eli Lilly And Company Herbicidal use of 4-amino-3,3-dimethyl-1-phenyl-2-azetidinones
US4304718A (en) * 1975-10-06 1981-12-08 Fujisawa Pharmaceutical Co., Ltd. 2-Azetidinone compounds and processes for preparation thereof
US4472309A (en) * 1975-10-06 1984-09-18 Fujisawa Pharmaceutical Co., Ltd. 2-Azetidinone compounds and processes for preparation thereof
US4576753A (en) * 1975-10-06 1986-03-18 Fujisawa Pharmaceutical Co., Ltd. Azetidinone compounds and processes for preparation thereof
US4166907A (en) * 1976-11-01 1979-09-04 E. R. Squibb & Sons, Inc. 3,3-Dichloro-2-azetidinone derivatives having antiinflammatory activity
US4144232A (en) * 1976-12-23 1979-03-13 Eli Lilly And Company Substituted azetidin-2-one antibiotics
FR2403078A1 (fr) * 1977-09-19 1979-04-13 Lafon Labor Nouveau procede de preparation de formes pharmaceutiques, cosmetiques ou de diagnostic
IT1157365B (it) * 1977-10-24 1987-02-11 Sandoz Ag Medicamenti per trattare l'obesita' o ridurre il peso del corpo
FR2408577A1 (fr) 1977-11-14 1979-06-08 Devinter Sa Nouveau procede de synthese d'esters para chlorobenzoyl phenoxy isobutyriques
NZ191762A (en) 1978-10-19 1982-09-14 Merck & Co Inc Hypocholesteremic composition containing cholesterol synthesis inhibitor and anion exchange resin
US4250191A (en) * 1978-11-30 1981-02-10 Edwards K David Preventing renal failure
US4375475A (en) * 1979-08-17 1983-03-01 Merck & Co., Inc. Substituted pyranone inhibitors of cholesterol synthesis
US4260743A (en) * 1979-12-31 1981-04-07 Gist-Brocades N.V. Preparation of β-lactams and intermediates therefor
US4444784A (en) * 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
ES488665A0 (es) 1980-02-15 1980-12-16 Especialidades Farmaco Terape Procedimiento de obtencion de un nuevo compuesto antiateros-clerotico
FR2494112B1 (enExample) 1980-11-19 1986-01-10 Laruelle Claude
DE3107100A1 (de) * 1981-02-20 1982-09-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen Azaprostacycline, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung
US4500456A (en) * 1981-03-09 1985-02-19 Eli Lilly And Company Preparation of 4-fluoroazetidinones using FClO3
US4784734A (en) * 1981-04-10 1988-11-15 Otsuka Kagaku Yakuhin Kabushiki Kaisha Azetidinone derivatives and process for the preparation of the same
US4602003A (en) * 1982-05-17 1986-07-22 Medical Research Foundation Of Oregon Synthetic compounds to inhibit intestinal absorption of cholesterol in the treatment of hypercholesterolemia
US4602005A (en) * 1982-05-17 1986-07-22 Medical Research Foundation Of Oregon Tigogenin cellobioside for treating hypercholesterolemia and atherosclerosis
US4534786A (en) * 1982-06-23 1985-08-13 Chevron Research Company 1-Alkyl derivatives of 3-aryloxy-4-(2-carbalkoxy)-phenyl-azet-2-ones as plant growth regulators
US4443372A (en) * 1982-06-23 1984-04-17 Chevron Research Company 1-Alkyl derivatives of 3-aryloxy-4-(2-carbalkoxy)-phenyl-azet-2-ones as plant growth regulators
US4595532A (en) * 1983-02-02 1986-06-17 University Of Notre Dame Du Lac N-(substituted-methyl)-azetidin-2-ones
CA1256650A (en) * 1983-03-25 1989-06-27 Toshinari Tamura Process of producing 2-azetidinone-4-substituted compounds, and medicaments containing the compounds
US4675399A (en) * 1983-03-28 1987-06-23 Notre Dame University Cyclization process for β-lactams
US4614614A (en) * 1983-03-28 1986-09-30 Ciba-Geigy Corporation Process for the manufacture of optically active azetidinones
WO1985004876A1 (fr) * 1984-04-24 1985-11-07 Takeda Chemical Industries, Ltd. Derives de 2-azetidinone et leur procede de preparation
US4576749A (en) * 1983-10-03 1986-03-18 E. R. Squibb & Sons, Inc. 3-Acylamino-1-carboxymethylaminocarbonyl-2-azetidinones
US5229381A (en) * 1983-12-01 1993-07-20 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
US4680391A (en) * 1983-12-01 1987-07-14 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
US5229510A (en) * 1983-12-01 1993-07-20 Merck & Co., Inc. β-lactams useful in determining the amount of elastase in a clinical sample
US4654362A (en) * 1983-12-05 1987-03-31 Janssen Pharmaceutica, N.V. Derivatives of 2,2'-iminobisethanol
FR2561916B1 (fr) * 1984-03-30 1987-12-11 Lafon Labor Forme galenique pour administration orale et son procede de preparation par lyophilisation d'une emission huile dans eau
US4633017A (en) * 1984-08-03 1986-12-30 E. R. Squibb & Sons, Inc. N-hydroxy protecting groups and process for the preparation of 3-acylamino-1-hydroxy-2-azetidinones
US4581170A (en) * 1984-08-03 1986-04-08 E. R. Squibb & Sons, Inc. N-hydroxyl protecting groups and process and intermediates for the preparation of 3-acylamino-1-hydroxy-2-azetidinones
US4576748A (en) * 1984-09-17 1986-03-18 Merck & Co., Inc. 3-Hydroxy-3-aminoethyl β-lactams
US4647576A (en) 1984-09-24 1987-03-03 Warner-Lambert Company Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis
US4620867A (en) * 1984-09-28 1986-11-04 Chevron Research Company 1-carbalkoxyalkyl-3-aryloxy-4-(substituted-2'-carboxyphenyl)-azet-2-ones as plant growth regulators and herbicides
AR240698A1 (es) * 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
US4642903A (en) * 1985-03-26 1987-02-17 R. P. Scherer Corporation Freeze-dried foam dosage form
US4680289A (en) * 1985-06-05 1987-07-14 Progenics, Inc. Treatment of obesity and diabetes using sapogenins
JPH0679559B2 (ja) 1985-06-06 1994-10-12 三共株式会社 光学活性アゼチジノン誘導体の製法
WO1987004429A1 (en) 1986-01-23 1987-07-30 The Upjohn Company Antimicrobial n-acyl-2-azetidinones
EP0234484B1 (en) * 1986-02-19 1993-10-20 Sanraku Incorporated Novel azetidinone derivatives
GB8607312D0 (en) * 1986-03-25 1986-04-30 Ici Plc Therapeutic agents
KR880701098A (ko) 1986-04-01 1988-07-25 로버어트 에이 아미테이지 메틸프레드니솔론/소디움 카르복시메틸 전분 정제 조성물
FR2598146B1 (fr) * 1986-04-30 1989-01-20 Rech Ind Nouveau procede de preparation de fibrates.
DE3621861A1 (de) * 1986-06-30 1988-01-14 Laszlo Dr Med Ilg Verwendung von aryloxycarbonsaeure-derivaten gegen dermatologische erkrankungen
JPS6317859A (ja) 1986-07-11 1988-01-25 Sagami Chem Res Center フルオロアゼチジノン誘導体
FR2602423B1 (fr) * 1986-08-08 1989-05-05 Ethypharm Sa Procede de preparation d'un medicament a base de fenofibrate, medicament obtenu par ce procede
US4814354A (en) * 1986-09-26 1989-03-21 Warner-Lambert Company Lipid regulating agents
IL84051A0 (en) 1986-10-03 1988-03-31 Lilly Co Eli 7-((meta-substituted)phenylglycine)1-carba-1-dethiacephalosporins
US4803266A (en) 1986-10-17 1989-02-07 Taisho Pharmaceutical Co., Ltd. 3-Oxoalkylidene-2-azetidinone derivatives
PH25145A (en) 1986-12-15 1991-02-19 Laverne Dwaine Boeck Process for producing the a10255 complex and corresponding microorganism
US5229362A (en) * 1986-12-15 1993-07-20 Eli Lilly And Company Antibiotic A10255 complex and factors, and process and production therefor
NZ222895A (en) 1986-12-15 1992-08-26 Lilly Co Eli Streptomyces gardneri strains and production of antibiotic a10255 complex and factors b, c, e, f and g; animal feed and pharmaceutical compositions
JPS63156788A (ja) * 1986-12-22 1988-06-29 Sanraku Inc 光学活性アゼチジノン類
AU1422388A (en) 1987-01-27 1988-08-10 Warner-Lambert Company Lipid regulating compositions
US5110730A (en) * 1987-03-31 1992-05-05 The Scripps Research Institute Human tissue factor related DNA segments
US4879301A (en) * 1987-04-28 1989-11-07 Hoei Pharmaceutical Co., Ltd. Antiallergic and antiinflammatory benzothiazolinone derivatives
GB8710965D0 (en) 1987-05-08 1987-06-10 Smith Kline French Lab Pharmaceutical compositions
US5106833A (en) * 1987-07-23 1992-04-21 Washington University Coagulation inhibitors
MY104063A (en) 1987-10-06 1993-11-30 Lilly Co Eli Crystalline (beta)-lactam hydrate
US5091525A (en) * 1987-10-07 1992-02-25 Eli Lilly And Company Monohydrate and DMF solvates of a new carbacephem antibiotic
US4834846A (en) * 1987-12-07 1989-05-30 Merck & Co., Inc. Process for deblocking N-substituted β-lactams
US5385885A (en) 1988-01-15 1995-01-31 Gasic; Gregory P. Inhibition of smooth muscle cell proliferation by antistasin and tick anticoagulant peptide
FR2627696B1 (fr) * 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
DE3807895A1 (de) * 1988-03-10 1989-09-21 Knoll Ag Erzeugnisse, enthaltend einen calciumantagonisten und einen lipidsenker
EP0333268A1 (en) 1988-03-18 1989-09-20 Merck & Co. Inc. Process for synthesis of a chiral 3-beta hydrogen (3R) 4-aroyloxy azetidinone
NZ228600A (en) 1988-04-11 1992-02-25 Merck & Co Inc 1-(benzylaminocarbonyl)-4-phenoxy-azetidin-2-one derivatives
GB8813012D0 (en) * 1988-06-02 1988-07-06 Norsk Hydro As Non-b-oxidizable fatty acid analogues to reduce concentration of cholesterol & triglycerides in blood of mammals
FR2634376B1 (fr) 1988-07-21 1992-04-17 Farmalyoc Nouvelle forme unitaire, solide et poreuse comprenant des microparticules et/ou des nanoparticules, ainsi que sa preparation
US4952689A (en) * 1988-10-20 1990-08-28 Taisho Pharmaceutical Co., Ltd. 3-(substituted propylidene)-2-azetidinone derivates for blood platelet aggregation
CA2002596A1 (en) 1988-11-14 1990-05-14 Thomas M. Eckrich Hydrates of b-lactam antibiotic
CA1340977C (en) 1988-11-15 2000-04-25 Monty Krieger Scavenger receptor protein and antibody thereto
US5073374A (en) * 1988-11-30 1991-12-17 Schering Corporation Fast dissolving buccal tablet
US5112616A (en) * 1988-11-30 1992-05-12 Schering Corporation Fast dissolving buccal tablet
US4876365A (en) * 1988-12-05 1989-10-24 Schering Corporation Intermediate compounds for preparing penems and carbapenems
US5260305A (en) 1988-12-12 1993-11-09 E. R. Squibb & Sons, Inc. Combination of pravastatin and nicotinic acid or related acid and method for lowering serum cholesterol using such combination
FR2640621B1 (fr) * 1988-12-19 1992-10-30 Centre Nat Rech Scient N-aryl-azetidinones, leur procede de preparation et leur utilisation comme inhibiteurs des elastases
US4990535A (en) * 1989-05-03 1991-02-05 Schering Corporation Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine
CA2016467A1 (en) 1989-06-05 1990-12-05 Martin Eisman Method for treating peripheral atherosclerotic disease employing an hmg coa reductase inhibitor and/or a squalene synthetase inhibitor
JPH03108490A (ja) * 1989-06-30 1991-05-08 Shionogi & Co Ltd フォスフォリパーゼa↓2阻害物質
US5021461A (en) * 1989-07-26 1991-06-04 Merrell Dow Pharmaceuticals Inc. Method of treating diabetes mellitus with bisphenol derivatives
US4983597A (en) 1989-08-31 1991-01-08 Merck & Co., Inc. Beta-lactams as anticholesterolemic agents
IL95574A (en) 1989-09-09 1994-11-11 Knoll Ag Colestyramine preparation
US5219574A (en) 1989-09-15 1993-06-15 Cima Labs. Inc. Magnesium carbonate and oil tableting aid and flavoring additive
US5178878A (en) * 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
US5223264A (en) * 1989-10-02 1993-06-29 Cima Labs, Inc. Pediatric effervescent dosage form
US5188825A (en) * 1989-12-28 1993-02-23 Iles Martin C Freeze-dried dosage forms and methods for preparing the same
CA2039763A1 (en) 1990-04-30 1991-10-31 Henry Y. Pan Combination of pravastatin and a fibric acid derivative, and method for treating dyslipidemia using such combination
CA2040865C (en) 1990-05-15 2002-07-23 James L. Bergey Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor
US5298497A (en) 1990-05-15 1994-03-29 E. R. Squibb & Sons, Inc. Method for preventing onset of hypertension employing a cholesterol lowering drug
CA2042526A1 (en) 1990-06-11 1991-12-12 Adeoye Y. Olukotun Method for preventing a second heart attack employing an hmg coa reductase inhibitor
US5622985A (en) 1990-06-11 1997-04-22 Bristol-Myers Squibb Company Method for preventing a second heart attack employing an HMG CoA reductase inhibitor
US5120729A (en) * 1990-06-20 1992-06-09 Merck & Co., Inc. Beta-lactams as antihypercholesterolemics
ZA915372B (en) * 1990-07-17 1993-03-31 Lilly Co Eli Pyrazolidinone cck and gastrin antagonists and pharmaceutical formulations thereof
CA2048395A1 (en) 1990-08-23 1992-02-24 Henry Y. Pan Method for preventing onset of or treating type iii hyperlipoproteinemia employing pravastatin
US5120713A (en) * 1990-09-10 1992-06-09 Applied Research Systems Ars Holding N.V. Treatment of obesity with an alpha-2-adrenergic agonist and a growth hormone releasing peptide
US5075313A (en) 1990-09-13 1991-12-24 Eli Lilly And Company 3-aryl-4(3H)quinazolinone CCK antagonists and pharmaceutical formulations thereof
IL99658A0 (en) 1990-10-15 1992-08-18 Merck & Co Inc Substituted azetidinones and pharmaceutical compositions containing them
CA2052014A1 (en) 1990-10-19 1992-04-20 Henry Y. Pan Method for preventing diabetic complications employing a cholesterol lowering drug alone or in combination with an ace inhibitor
US5190970A (en) * 1990-10-19 1993-03-02 E. R. Squibb & Sons, Inc. Method for preventing onset of or treating Type II diabetes employing a cholesterol lowering drug alone or in combination with an ace inhibitor
US5130333A (en) * 1990-10-19 1992-07-14 E. R. Squibb & Sons, Inc. Method for treating type II diabetes employing a cholesterol lowering drug
JP2640986B2 (ja) * 1990-11-08 1997-08-13 高砂香料工業株式会社 (1′r,3s)―3―(1′―ヒドロキシエチル)―アゼチジン―2―オン又はその誘導体の製造法
IL100091A (en) 1990-12-12 1998-08-16 Zeneca Ltd Pharmaceutical compositions containing a physical form of n-[4-[5-(cyclopentyloxycarbonyl)amino-1-methyl indol-3-yl-methyl]-2-methylbenzenesulpho-namide and process for their preparation
US5552160A (en) 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
AU642066B2 (en) 1991-01-25 1993-10-07 Nanosystems L.L.C. X-ray contrast compositions useful in medical imaging
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
IT1244699B (it) 1991-02-01 1994-08-08 Luso Farmaco Inst Processo per la preparazione di acidi 3 acilammino-4- carbamoilossimetil-2-azetidinone-l-solfonici ed intermedi per la loro preparazione
US5157025A (en) * 1991-04-01 1992-10-20 E. R. Squibb & Sons, Inc. Method for lowering serum cholesterol employing a phosphorus containing ace inhibitor alone or in combination with a cholesterol lowering drug
US5348953A (en) 1991-06-25 1994-09-20 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
US5464632C1 (en) 1991-07-22 2001-02-20 Prographarm Lab Rapidly disintegratable multiparticular tablet
ES2107548T3 (es) 1991-07-23 1997-12-01 Schering Corp Compuestos de beta-lactama sustituidos utiles como agentes hipocolesterolemicos y procedimientos para su preparacion.
US5688787A (en) * 1991-07-23 1997-11-18 Schering Corporation Substituted β-lactam compounds useful as hypochlesterolemic agents and processes for the preparation thereof
US5561227A (en) 1991-07-23 1996-10-01 Schering Corporation Process for the stereospecific synthesis of azetidinones
US5688785A (en) 1991-07-23 1997-11-18 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
JP2620437B2 (ja) 1991-09-27 1997-06-11 宇部興産株式会社 ω−ヒドロキシ−(ω−3)−ケトニトリルおよびω−ヒドロキシ脂肪酸の製法
ES2114948T3 (es) 1991-10-04 1998-06-16 Procter & Gamble Compuestos disminuidores del colesterol y procedimiento para prepararlos.
US5162117A (en) * 1991-11-22 1992-11-10 Schering Corporation Controlled release flutamide composition
FI942394A7 (fi) 1991-11-25 1994-05-24 Pfizer Menetelmä steroidiperasyyliglykosidien valmistamiseksi
DE4203932A1 (de) 1992-02-11 1993-08-12 Deutsche Aerospace Sende-/empfangsmodul
US6063764A (en) 1992-06-01 2000-05-16 Washington University & Chiron Corp. Method for using lipoprotein associated coagulation inhibitor to treat sepsis
EP0647234A1 (en) 1992-06-26 1995-04-12 Pfizer Inc. Steroidal glycosides for treating hypercholesterolemia
US5278176A (en) 1992-08-21 1994-01-11 Abbott Laboratories Nicotine derivatives that enhance cognitive function
CA2147129A1 (en) 1992-10-27 1994-05-11 James B. Doherty New substituted azetidinones as anti-inflammatory and antidegenerative agents
US5631363A (en) 1992-11-13 1997-05-20 Tanabe Seiyaku Co., Ltd. Azetidinone compound and process for preparation thereof
NZ248813A (en) 1992-11-25 1995-06-27 Eastman Kodak Co Polymeric grinding media used in grinding pharmaceutical substances
WO1994020535A1 (en) 1992-12-11 1994-09-15 Corvas International, Inc. ECOTIN AS A FACTOR Xa, XIa, AND XIIa INHIBITOR
US5429824A (en) 1992-12-15 1995-07-04 Eastman Kodak Company Use of tyloxapole as a nanoparticle stabilizer and dispersant
US5358852A (en) 1992-12-21 1994-10-25 Eastman Kodak Company Use of calcium in immunoassay for measurement of C-reactive protein
LT3300B (en) 1992-12-23 1995-06-26 Schering Corp Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor
LT3595B (en) 1993-01-21 1995-12-27 Schering Corp Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents
US5563264A (en) 1993-02-10 1996-10-08 Shionogi & Co., Ltd. Preparation of βlactam compounds
US5503846A (en) 1993-03-17 1996-04-02 Cima Labs, Inc. Base coated acid particles and effervescent formulation incorporating same
US5412092A (en) 1993-04-23 1995-05-02 Bristol-Myers Squibb Company N-substituted 2-azetidinones
IL109568A0 (en) 1993-05-19 1994-08-26 Fujisawa Pharmaceutical Co Urea derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof
US5703188A (en) 1993-06-02 1997-12-30 Geltex Pharmaceuticals, Inc. Process for removing bile salts from a patient and compositions therefor
US5550229A (en) 1993-06-23 1996-08-27 Tanabe Seiyaku Co., Ltd. Alkylation process for preparing azetidinone compound and starting compound therefor
KR0176001B1 (ko) 1993-07-09 1999-03-20 에릭 에스. 딕커 아제티디논의 합성방법
US5631023A (en) 1993-07-09 1997-05-20 R.P. Scherer Corporation Method for making freeze dried drug dosage forms
WO1995004533A2 (en) 1993-08-04 1995-02-16 Andrulis Pharmaceuticals Corporation Treatment of rheumatoid arthritis with thalidomide alone or in combination with other anti-inflammatory agents
AU7397094A (en) 1993-08-30 1995-03-22 Merck & Co., Inc. Prevention and treatment of alzheimer's disease
US5622719A (en) 1993-09-10 1997-04-22 Fuisz Technologies Ltd. Process and apparatus for making rapidly dissolving dosage units and product therefrom
US5895664A (en) 1993-09-10 1999-04-20 Fuisz Technologies Ltd. Process for forming quickly dispersing comestible unit and product therefrom
US5851553A (en) 1993-09-10 1998-12-22 Fuisz Technologies, Ltd. Process and apparatus for making rapidly dissolving dosage units and product therefrom
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5976570A (en) 1993-12-21 1999-11-02 Applied Analytical Industries, Inc. Method for preparing low dose pharmaceutical products
JPH09500906A (ja) 1993-12-28 1997-01-28 ファイザー・インク. 血中コレステロール低下薬
US6369103B1 (en) 1994-01-18 2002-04-09 Bristol-Myers Squibb Company Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor
US5595761A (en) 1994-01-27 1997-01-21 The Board Of Regents Of The University Of Oklahoma Particulate support matrix for making a rapidly dissolving tablet
US5576014A (en) 1994-01-31 1996-11-19 Yamanouchi Pharmaceutical Co., Ltd Intrabuccally dissolving compressed moldings and production process thereof
GB9401892D0 (en) 1994-02-01 1994-03-30 Boots Co Plc Therapeutic agents
US5635210A (en) 1994-02-03 1997-06-03 The Board Of Regents Of The University Of Oklahoma Method of making a rapidly dissolving tablet
US5627176A (en) * 1994-03-25 1997-05-06 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
GB9406074D0 (en) 1994-03-26 1994-05-18 Glaxo Spa Chemical process
DE4414538A1 (de) 1994-04-26 1995-11-02 Klinge Co Chem Pharm Fab Präparate zur Therapie der kombinierten Hyperlipidämie mit einem Gehalt an einem p-Oxybenzoesäurederivat und einem Fibrat
US5554746A (en) 1994-05-16 1996-09-10 Isis Pharmaceuticals, Inc. Lactam nucleic acids
TW384224B (en) 1994-05-25 2000-03-11 Nano Sys Llc Method of preparing submicron particles of a therapeutic or diagnostic agent
US5718388A (en) 1994-05-25 1998-02-17 Eastman Kodak Continuous method of grinding pharmaceutical substances
US5567439A (en) 1994-06-14 1996-10-22 Fuisz Technologies Ltd. Delivery of controlled-release systems(s)
WO1995035277A1 (en) * 1994-06-20 1995-12-28 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
US6429289B1 (en) 1994-06-23 2002-08-06 Massachusetts Institute Of Technology Class BI and CI scavenger receptors
CA2200436A1 (en) 1994-09-20 1996-04-04 Pfizer Inc. Combination therapy for hypercholesterolemia
GB9421836D0 (en) 1994-10-28 1994-12-14 Scherer Corp R P Process for preparing solid pharmaceutical dosage forms of hydrophobic substances
GB9421816D0 (en) 1994-10-29 1994-12-14 Smithkline Beecham Plc Novel compounds
US5633246A (en) 1994-11-18 1997-05-27 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5624920A (en) 1994-11-18 1997-04-29 Schering Corporation Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US5656624A (en) 1994-12-21 1997-08-12 Schering Corporation 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
AU704407B2 (en) 1994-12-22 1999-04-22 Smithkline Beecham Plc Substituted azetidin-2-ones for treatment of atherosclerosis
US5902726A (en) 1994-12-23 1999-05-11 Glaxo Wellcome Inc. Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma
SK282144B6 (sk) 1994-12-28 2001-11-06 Janssen Pharmaceutica N. V. Liečivo na terapeutické a profylaktické ošetrenie degeneratívnych chorôb vaskulárneho systému a nervovej sústavy, ktoré súvisia s oxidačným stresom
US5545628A (en) 1995-01-10 1996-08-13 Galephar P.R. Inc. Pharmaceutical composition containing fenofibrate
FR2730231B1 (fr) 1995-02-02 1997-04-04 Fournier Sca Lab Association de fenofibrate et de vitamine e, utilisation en therapeutique
US5639475A (en) 1995-02-03 1997-06-17 Eurand America, Incorporated Effervescent microcapsules
US5518738A (en) 1995-02-09 1996-05-21 Nanosystem L.L.C. Nanoparticulate nsaid compositions
US5591456A (en) 1995-02-10 1997-01-07 Nanosystems L.L.C. Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5747001A (en) 1995-02-24 1998-05-05 Nanosystems, L.L.C. Aerosols containing beclomethazone nanoparticle dispersions
US5998441A (en) 1995-02-28 1999-12-07 Eli Lilly And Company Benzothiophene compounds, intermediates, compositions, and methods
US5639739A (en) 1995-03-24 1997-06-17 The Dupont Merck Pharmaceutical Company Imidazole containing aminoboronic acids
US5759865A (en) 1995-05-03 1998-06-02 Eli Lilly And Company Combinatorial process for synthesizing azetidinone analogs
DE19518988A1 (de) 1995-05-29 1996-12-05 Basf Ag Verwendung arylsubstituierter Cyclobutylalkylamine zur Behandlung der Fettleibigkeit
JP3144624B2 (ja) 1995-06-02 2001-03-12 杏林製薬株式会社 N−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法
US5612378A (en) 1995-06-06 1997-03-18 3-Dimensional Pharmaceuticals, Inc. Bis-arylsulfonylaminobenzamide derivatives and the use thereof as factor Xa inhibitors
WO1996040255A2 (en) 1995-06-07 1996-12-19 G.D. Searle & Co. Method to treat cardiofibrosis with a combination therapy of an angiotensin ii antagonist and an epoxy-steroidal aldosterone antagonist
US5612353A (en) 1995-06-07 1997-03-18 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted (sulfinic acid, sulfonic acid, sulfonylamino or sulfinylamino) N-[(aminoiminomethyl)phenylalkyl]-azaheterocyclylamide compounds
US5607697A (en) 1995-06-07 1997-03-04 Cima Labs, Incorporated Taste masking microparticles for oral dosage forms
NO318765B1 (no) 1995-07-03 2005-05-02 Sankyo Co Anvendelse av en HMG-CoA reduktaseinhibitor og en insulinsensibilisator til fremstilling av et medikament for forebyggelse eller behandling av arteriosklerose eller xantom, samt pakket farmasoytisk preparat som omfatter de to midlene i separate porsjoner.
FR2737121B1 (fr) 1995-07-27 1997-10-03 Cl Pharma Nouvelles formulations galeniques du fenofibrate et leurs applications
US5698527A (en) 1995-08-08 1997-12-16 Merck & Co., Inc. Steroidal glycosides as antihyperlipidemic agents
FR2738817B1 (fr) 1995-09-14 1997-10-17 Adir Nouveaux acides et esters 2,2-dimethyl-omega-phenoxy alcanoiques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US5618707A (en) 1996-01-04 1997-04-08 Schering Corporation Stereoselective microbial reduction of 5-fluorophenyl-5-oxo-pentanoic acid and a phenyloxazolidinone condensation product thereof
SK283552B6 (sk) 1995-10-31 2003-09-11 Schering Corporation 2-Azetidinóny substituované cukrovými zvyškami, farmaceutický prípravok, kombinovaný farmaceutický prípravok a ich použitie
US5808056A (en) 1995-10-31 1998-09-15 Merck & Co., Inc. Process for preparing substituted azetidinones
WO1997016424A1 (en) 1995-11-02 1997-05-09 Schering Corporation Process for preparing 1-(4-fluorophenyl)-3(r)-(3(s)-hydroxy-3-([phenyl or 4-fluorophenyl])-propyl)-4(s)-(4-hydroxyphenyl)-2-azetidinone
US5955105A (en) 1995-11-14 1999-09-21 Knoll Pharmaceutical Company Stabilized thyroid hormone preparations and methods of making same
US5925333A (en) 1995-11-15 1999-07-20 Massachusetts Institute Of Technology Methods for modulation of lipid uptake
JPH09143156A (ja) 1995-11-17 1997-06-03 Tanabe Seiyaku Co Ltd アセトキシアゼチジノン誘導体の製法及びその合成中間体
US5807578A (en) 1995-11-22 1998-09-15 Lab Pharmaceutical Research International Inc. Fast-melt tablet and method of making same
US5807577A (en) 1995-11-22 1998-09-15 Lab Pharmaceutical Research International Inc. Fast-melt tablet and method of making same
EP0865429A1 (en) 1995-12-08 1998-09-23 Smithkline Beecham Plc Azetidinone compounds for the treatment of atherosclerosis
US6080767A (en) 1996-01-02 2000-06-27 Aventis Pharmaceuticals Products Inc. Substituted n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides
GB9600464D0 (en) 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
US5859051A (en) 1996-02-02 1999-01-12 Merck & Co., Inc. Antidiabetic agents
US5847008A (en) 1996-02-02 1998-12-08 Merck & Co., Inc. Method of treating diabetes and related disease states
AU1856997A (en) 1996-02-02 1997-08-22 Merck & Co., Inc. Method for raising hdl cholesterol levels
GB9604242D0 (en) 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
DE19608750A1 (de) 1996-03-06 1997-09-11 Durachemie Gmbh & Co Kg Verfahren zur Herstellung von Fenofibrat-Präparaten
IL117702A0 (en) 1996-03-28 1996-07-23 Tel Aviv Medical Center Resear Drug for hyperlipoproteinemia
GB9606805D0 (en) 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
CA2251972A1 (en) * 1996-04-17 1997-10-23 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardiovascular disease
US5858409A (en) 1996-04-17 1999-01-12 Fmc Corporation Hydrolyzed cellulose granulations for pharmaceuticals
JP2000509049A (ja) 1996-04-26 2000-07-18 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー アテローム性動脈硬化症の治療用アゼチジノン誘導体
US5843984A (en) 1996-05-09 1998-12-01 Eli Lilly And Company Sulfated benzothiophene derivatives, methods of use and formulations containing same
ZA974428B (en) * 1996-05-24 1997-11-24 Schering Corp Antifungal composition with enhanced bioavailability.
US5739321A (en) 1996-05-31 1998-04-14 Schering Corporation 3-hydroxy γ-lactone based enantionselective synthesis of azetidinones
US5886171A (en) 1996-05-31 1999-03-23 Schering Corporation 3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones
US6245743B1 (en) 1996-06-05 2001-06-12 Cor Therapeutics, Inc. Inhibitors of factor Xa
GB9611947D0 (en) 1996-06-07 1996-08-07 Glaxo Group Ltd Medicaments
US5998421A (en) 1996-06-12 1999-12-07 Kyowa Hakko Kogyo Co., Ltd. Lipid metabolism ameliorants
US5965553A (en) 1996-06-20 1999-10-12 Pfizer Inc. Squalene synthetase inhibitors
WO1998001119A2 (en) 1996-07-09 1998-01-15 Merck & Co., Inc. Pharmaceutical compositions comprising simvastatin
US6139873A (en) 1996-07-10 2000-10-31 Cedars-Sinai Medical Center Combined pharmaceutical estrogen-androgen-progestin
US5883109A (en) 1996-07-24 1999-03-16 Bristol-Myers Squibb Company Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug
US5952003A (en) 1996-08-01 1999-09-14 Novartis Corporation Terazosin capsules
AU4050797A (en) 1996-08-02 1998-02-25 Ligand Pharmaceuticals Incorporated Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators
US6057342A (en) 1996-08-16 2000-05-02 Dupont Pharmaceutical Co. Amidinophenyl-pyrrolidines, -pyrrolines, and -isoxazolidines and derivatives thereof
US6235706B1 (en) 1996-09-18 2001-05-22 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardiovascular disease
US6251852B1 (en) 1996-09-18 2001-06-26 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardiovascular disease
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
EP0950046B1 (en) 1996-09-23 2002-04-10 Naeja Pharmaceutical Inc. 3,4-disubstituted azetidin-2-one derivatives useful as cysteine proteinase regulators
US6139865A (en) 1996-10-01 2000-10-31 Eurand America, Inc. Taste-masked microcapsule compositions and methods of manufacture
US6262047B1 (en) 1996-10-11 2001-07-17 Cor Therapeutics, Inc. Selective factor Xa inhibitors
US5756470A (en) 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
CZ298552B6 (cs) 1996-11-27 2007-10-31 Aventis Pharmaceuticals Inc. Farmaceutický prostredek a použití tohoto prostredku pro prípravu léciva
US6090839A (en) 1996-12-23 2000-07-18 Merck & Co., Inc. Antidiabetic agents
FR2758461A1 (fr) 1997-01-17 1998-07-24 Pharma Pass Composition pharmaceutique presentant une biodisponibilite elevee et son procede de preparation
US6066653A (en) 1997-01-17 2000-05-23 Bristol-Myers Squibb Co. Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs
WO1998031366A1 (en) 1997-01-17 1998-07-23 Bristol-Myers Squibb Company Method for treating atherosclerosis with an mpt inhibitor and cholesterol lowering drugs
FR2758459B1 (fr) 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
BR9807873A (pt) * 1997-02-28 2000-03-21 Oravax Inc Vacinas de flavivìrus quiméricos
WO1998043081A1 (en) 1997-03-26 1998-10-01 Ligand Pharmaceuticals Incorporated Treatment of gastrointestinal disease with ppar modulators
FR2761266B1 (fr) * 1997-03-28 1999-07-02 Sanofi Sa Composition pharmaceutique formee par granulation humide pour l'administration orale d'un derive du n-piperidino-3- pyrazolecarboxamide, de ses sels et de leurs solvates
ES2239801T3 (es) 1997-04-02 2005-10-01 The Brigham And Women's Hospital, Inc. Uso de un agente para disminuir el riesgo de enfermedad cardiovascular.
US6024981A (en) 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
DE19716120A1 (de) 1997-04-17 1998-10-22 Europ Lab Molekularbiolog Verwendung von cholesterinsenkenden Mitteln
EP0977573A1 (en) 1997-04-24 2000-02-09 MERCK SHARP & DOHME LTD. Use of an nk-1 receptor antagonist and an ssri for treating obesity
ES2125198B1 (es) * 1997-05-13 1999-11-16 Vita Invest Sa Asociacion a dosis fija de un inhibidor de la enzima convertidora de angiotensina y de un antagonista de los canales de calcio, procedimiento para su preparacion y su utilizacion para el tratamiento de enfermees cardiovasculares.
CN1275596C (zh) 1997-05-14 2006-09-20 阿特罗吉尼克斯公司 普罗布考单酯在制备用于治疗心血管疾病和炎性疾病的药物中的应用
US6423754B1 (en) 1997-06-18 2002-07-23 Geltex Pharmaceuticals, Inc. Method for treating hypercholesterolemia with polyallylamine polymers
WO1999004815A1 (fr) 1997-07-24 1999-02-04 Yamanouchi Pharmaceutical Co., Ltd. Compositions medicinales hypocholesterolemiantes
US20010006644A1 (en) 1997-07-31 2001-07-05 David J. Bova Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night
DE69837610T2 (de) 1997-07-31 2008-01-03 Kos Life Sciences, Inc., Weston Manteltablette enthaltend nikotinsäure oder einen stoff, der zu nikotinsäure metabolisiert wird in verzögert freigesetzter form und einen hmg-coa reduktasehemmer im mantel zur sofortigen freisetzung
US6117429A (en) 1997-08-11 2000-09-12 Weider Nutrition International, Inc Compositions and treatments for reducing potential unwanted side effects associated with long-term administration of androgenic testosterone precursors
US5886191A (en) 1997-08-18 1999-03-23 Dupont Pharmaceuticals Company Amidinoindoles, amidinoazoles, and analogs thereof
US5869098A (en) 1997-08-20 1999-02-09 Fuisz Technologies Ltd. Fast-dissolving comestible units formed under high-speed/high-pressure conditions
AR016827A1 (es) * 1997-08-22 2001-08-01 Smithkline Beecham Corp PROCEDIMIENTO PARA LA PREPARACIoN DE UNA TABLETA FARMACÉUTICA
WO1999009967A2 (en) 1997-08-26 1999-03-04 Merck & Co., Inc. Cholesterol-lowering therapy
US6180660B1 (en) 1997-08-26 2001-01-30 Merck & Co., Inc. Cholesterol-lowering therapy
US6143885A (en) 1997-08-27 2000-11-07 Merck & Co., Inc. Preparation of beta-methyl carbapenem intermediates
GT199800126A (es) 1997-08-29 2000-01-29 Terapia de combinacion.
EP1015429B1 (en) 1997-09-09 2004-05-12 Bristol-Myers Squibb Pharma Company Benzimidazolinones, benzoxazolinones, benzopiperazinones, indanones, and derivatives thereof as inhibitors of factor xa
WO1999012534A1 (en) 1997-09-10 1999-03-18 Ono Pharmaceutical Co., Ltd. Peroxisome proliferator-activated receptor controllers
GB2329334A (en) 1997-09-18 1999-03-24 Reckitt & Colmann Prod Ltd Cholesterol-lowering agents
CA2214895C (en) 1997-09-19 1999-04-20 Bernard Charles Sherman Improved pharmaceutical composition comprising fenofibrate
WO1999015520A1 (en) 1997-09-19 1999-04-01 Ono Pharmaceutical Co., Ltd. Fused or nonfused benzene compounds
AU9454098A (en) 1997-09-24 1999-04-12 Nova Molecular, Inc. Methods for increasing apoe levels for the treatment of neurodegenerative disease
ATE224872T1 (de) 1997-10-07 2002-10-15 Boehringer Ingelheim Ca Ltd Azetidinonderivate zur behandlung von hcmv entzündungen
IE970731A1 (en) 1997-10-07 2000-10-04 Fuisz Internat Ltd Product and method for the treatment of hyperlipidemia
US6147109A (en) 1997-10-14 2000-11-14 The General Hospital Corporation Upregulation of Type III endothelial cell Nitric Oxide Synthase by HMG-CoA reductase inhibitors
US6005102A (en) 1997-10-15 1999-12-21 American Home Products Corporation Aryloxy-alkyl-dialkylamines
CN1302206A (zh) 1997-10-17 2001-07-04 阿温蒂斯药物制品公司 喹啉衍生物的治疗用途
WO1999022728A1 (en) 1997-10-31 1999-05-14 Arch Development Corporation Methods and compositions for regulation of 5-alpha reductase activity
US20030153541A1 (en) 1997-10-31 2003-08-14 Robert Dudley Novel anticholesterol compositions and method for using same
US6027747A (en) 1997-11-11 2000-02-22 Terracol; Didier Process for the production of dry pharmaceutical forms and the thus obtained pharmaceutical compositions
WO1999029300A1 (en) 1997-12-10 1999-06-17 Rtp Pharma Inc. Self-emulsifying fenofibrate formulations
US5985936A (en) 1997-12-18 1999-11-16 Forbes Medi-Tech, Inc. Method of preventing and delaying onset of Alzheimer's disease and composition therefor
US6008237A (en) 1997-12-19 1999-12-28 Merck & Co., Inc. Arylthiazolidinedione derivatives
JP2002501887A (ja) 1998-01-28 2002-01-22 ワーナー−ランバート・カンパニー アルツハイマー病の治療方法
AU1887999A (en) 1998-01-29 1999-08-16 Dr. Reddy's Research Foundation Novel alkanoic acids and their use in medicine, process for their preparation and pharmaceutical compositions containing them
CA2318731C (en) 1998-01-29 2012-05-29 Tularik Inc. Ppar-gamma modulators
US6133001A (en) 1998-02-23 2000-10-17 Schering Corporation Stereoselective microbial reduction for the preparation of 1-(4-fluorophenyl)-3(R)-[3(S)-Hydroxy-3-(4-fluorophenyl)propyl)]-4(S)-(4 -hydroxyphenyl)-2-azetidinone
DE69941777D1 (de) 1998-03-10 2010-01-21 Ono Pharmaceutical Co Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten
US6235311B1 (en) 1998-03-18 2001-05-22 Bristol-Myers Squibb Company Pharmaceutical composition containing a combination of a statin and aspirin and method
US6080778A (en) 1998-03-23 2000-06-27 Children's Medical Center Corporation Methods for decreasing beta amyloid protein
US6180625B1 (en) 1998-03-24 2001-01-30 Novo Nordisk A/S Heterocyclic compounds regulating clotting
AU3110999A (en) 1998-03-27 1999-10-18 Du Pont Pharmaceuticals Company Disubstituted pyrazolines and triazolines as factor xa inhibitors
ATE286032T1 (de) * 1998-04-23 2005-01-15 Reddys Lab Ltd Dr Heterozyklische verbindungen,und deren verwendung in arzneimittel,verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen
BR9910583A (pt) 1998-04-29 2001-01-09 Ortho Mcneil Pharm Inc Aminotetralinas n-substituìdas como ligantes para o receptor de neuropeptìdeo y y5 úteis no tratamento de obesidade e outros distúrbios
EP1082313A1 (en) 1998-05-27 2001-03-14 Dr. Reddy's Research Foundation Bicyclic compounds, process for their preparation and pharmaceutical compositions containing them
US6262042B1 (en) 1998-05-29 2001-07-17 Research Triangle Institute 17β-amino and hydroxylamino-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
FR2779347A1 (fr) 1998-06-05 1999-12-03 Arlette Guerry Procede de micronisation de substances medicamenteuses
EP1089732A4 (en) 1998-06-24 2001-09-19 Merck & Co Inc COMPOSITIONS AND METHODS FOR TREATING INCREASED BLOOD CHOLESTEROL LEVELS
JP2002518448A (ja) 1998-06-24 2002-06-25 メルク エンド カムパニー インコーポレーテッド 高血中コレステロールを治療する組成物および方法
US6099865A (en) 1998-07-08 2000-08-08 Fmc Corporation Croscarmellose taste masking
FR2781222A1 (fr) 1998-07-17 2000-01-21 Lipha Composes cycliques utilisables dans le traitement de dyslipidemies, de l'atherosclerose et du diabete, compositions pharmaceutiques les contenant et procede de preparation
EP1100530B1 (en) 1998-07-31 2003-10-08 Novo Nordisk A/S In-vitro stimulation of beta cell proliferation
ATE315033T1 (de) 1998-08-07 2006-02-15 Chiron Corp Subtituierte isoxazole derivate als estrogen rezeptor modulatore
US6147090A (en) 1998-09-17 2000-11-14 Pfizer Inc. 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
FR2783421B1 (fr) 1998-09-17 2000-11-24 Cll Pharma Procede de preparation de nouvelles formulations galeniques du fenofibrate, formulations galeniques obtenues par ledit procede et leurs applications
OA11787A (en) 1998-09-30 2005-07-26 Warner Lambert Co Method for preventing or delaying catheter-based revascularization.
US5919672A (en) 1998-10-02 1999-07-06 Schering Corporation Resolution of trans-2-(alkoxycarbonylethyl)-lactams useful in the synthesis of 1-(4-fluoro-phenyl)-3(R)- (S)-hydroxy-3-(4-fluorophenyl)-propyl!-4(S)-(4-hydroxyphenyl)-2-azetidinone
JP2002527507A (ja) 1998-10-21 2002-08-27 ノボ ノルディスク アクティーゼルスカブ 新規化合物類、それらの調製及び使用
WO2000023451A1 (en) 1998-10-21 2000-04-27 Novo Nordisk A/S New compounds, their preparation and use
EP1123267A1 (en) 1998-10-21 2001-08-16 Novo Nordisk A/S New compounds, their preparation and use
US6248781B1 (en) 1998-10-21 2001-06-19 Novo Nordisk A/S Compounds useful in the treatment of conditions mediated by peroxisome proliferator-activated receptors (PPAR)
JP2002527516A (ja) 1998-10-21 2002-08-27 ノボ ノルディスク アクティーゼルスカブ 新規化合物、それらの製造及び使用
EP1123268A1 (en) 1998-10-21 2001-08-16 Novo Nordisk A/S New compounds, their preparation and use
CA2253769C (en) 1998-11-10 2000-09-26 Bernard Charles Sherman Pharmaceutical compositions comprising fenofibrate
US6472421B1 (en) 1998-11-13 2002-10-29 Nymox Corporation Methods for treating, preventing, and reducing the risk of the onset of alzheimer's disease using an HMG CoA reductase inhibitor
JP2002530122A (ja) 1998-11-25 2002-09-17 サイオス インコーポレイテッド アミロイド関連疾患の予防及び治療
SA99191255B1 (ar) 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
US6207822B1 (en) 1998-12-07 2001-03-27 Schering Corporation Process for the synthesis of azetidinones
CN1130342C (zh) 1998-12-07 2003-12-10 先灵公司 β-丙内酰胺的合成方法
US6277584B1 (en) 1998-12-16 2001-08-21 Dade Behring Inc. Method for calibrating a chemical analyzer with improved accuracy at low signal levels
DE19858789A1 (de) 1998-12-18 2000-06-21 Bayer Ag Kombination von Cerivastatin und Fibraten
JP2002532539A (ja) 1998-12-18 2002-10-02 アボット・ラボラトリーズ 脂質調節剤を含む新規な製剤
CZ20012342A3 (cs) 1998-12-23 2001-12-12 G. D. Searle Llc Kombinace inhibitorů transportu ľlučové kyseliny v ileu a derivátů kyseliny fibrové pro kardiovaskulární indikace
HUP0104745A3 (en) 1998-12-23 2003-01-28 G D Searle Llc Chicago Combinations of ileal bile acid transport inhibitors and bile acid sequestring agents for cardiovascular indications
ATE242007T1 (de) 1998-12-23 2003-06-15 Searle Llc Kombinationen von cholesteryl ester transfer protein inhibitoren und nicotinsäure derivaten für kardiovaskuläre indikationen
US6462091B1 (en) 1998-12-23 2002-10-08 G.D. Searle & Co. Combinations of cholesteryl ester transfer protein inhibitors and HMG coA reductase inhibitors for cardiovascular indications
JP2002533411A (ja) * 1998-12-23 2002-10-08 ジー.ディー.サール エルエルシー 心臓血管に適用するための組み合わせ
AU2157500A (en) 1998-12-23 2000-07-31 G.D. Searle Llc Combinations of cholesteryl ester transfer protein inhibitors and bile acid sequestering agents for cardiovascular indications
IL143938A0 (en) 1998-12-23 2002-04-21 Searle Llc Combinations of ileal bile acid transport inhibitors and nicotinic acid derivatives for cardiovascular indications
CA2356422C (en) 1998-12-23 2008-09-16 G.D. Searle Llc Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications
ES2201827T3 (es) 1998-12-23 2004-03-16 G.D. Searle Llc Combinaciones de inhibidores de la proteina de transferencia de ester de colesterilo y de derivados de acido fibrico para indicaciones cardiovasculares.
AR022204A1 (es) 1999-01-08 2002-09-04 Norgine Bv Compuesto, proceso para su preparacion, composicion farmaceutica y producto comestible que lo comprende.
US6180138B1 (en) 1999-01-29 2001-01-30 Abbott Laboratories Process for preparing solid formulations of lipid-regulating agents with enhanced dissolution and absorption
GB0000710D0 (en) 1999-02-06 2000-03-08 Zeneca Ltd Drug combination
AU2690600A (en) 1999-02-24 2000-09-14 Fuji Chemical Industries, Ltd. 2-mercaptocarboxylic acid derivatives
EP1036563A1 (en) 1999-03-08 2000-09-20 MERCK & CO. INC. Delayed-release oral formulation of dihydroxy open acid simvastatin and salts and esters thereof
AU2866400A (en) 1999-03-08 2000-09-28 Merck & Co., Inc. Dihydroxy open-acid and salts of hmg-co-a reductase inhibitors
JP2002538189A (ja) 1999-03-10 2002-11-12 ジー.ディー.サール アンド カンパニー シクロオキシゲナーゼ−2インヒビターの投与方法と組成物
EP1176134A4 (en) 1999-03-11 2004-06-30 Arigen Inc PPAR NUCLEAR RECEPTOR LIGANDS
WO2000056403A1 (en) 1999-03-19 2000-09-28 The Brigham And Women's Hospital, Inc. UPREGULATION OF TYPE III ENDOTHELIAL CELL NITRIC OXIDE SYNTHASE BY HMG-CoA REDUCTASE INHIBITORS
AU4017500A (en) 1999-03-31 2000-10-16 Abbott Laboratories Novel formulations comprising lipid-regulating agents
HK1043936A1 (zh) 1999-03-31 2002-10-04 Abbott Laboratories 含有脂调节剂的新的配方
AU3382699A (en) 1999-04-05 2000-10-23 Schering Corporation Stereoselective microbial reduction for the preparation of - (4-fluorophenyl) - 3(r)-(3(s) - hydroxy-3 (4-fluorophenyl) propyl))-4(s) (4-hydroxyphenyl)-2-azetidinone
WO2000063703A1 (en) 1999-04-16 2000-10-26 Schering Corporation Use of azetidinone compounds
AU4250200A (en) 1999-04-19 2000-11-02 Coelacanth Corporation Ppar-(gamma) agonists as agents for the treatment of type ii diabetes
JP2002542237A (ja) 1999-04-20 2002-12-10 ノボ ノルディスク アクティーゼルスカブ 新規な化合物、それらの製造及び使用
AU3958200A (en) 1999-04-20 2000-11-02 Novo Nordisk A/S New compounds, their preparation and use
JP2002542218A (ja) 1999-04-20 2002-12-10 ノボ ノルディスク アクティーゼルスカブ 新規な化合物、それらの製造および使用
AU3958100A (en) 1999-04-20 2000-11-02 Novo Nordisk A/S New compounds, their preparation and use
CA2270306C (en) 1999-04-27 2000-09-26 Bernard Charles Sherman Pharmaceutical compositions comprising co-micronized fenofibrate
US6033656A (en) 1999-05-04 2000-03-07 Sumitomo Chemical Company, Limited Method of preventing or alleviating mammalian obesity
AU3988099A (en) 1999-05-13 2000-12-05 Geltex Pharmaceuticals, Inc. Combination therapy for treating hypercholesterolemia
CA2373681A1 (en) 1999-05-14 2000-11-23 Dennis I. Goldberg Pharmaceutical compositions for treating angina and/or anginal equivalents, and kit relating thereto
CA2374117A1 (en) 1999-05-28 2000-12-07 Abbott Laboratories Novel formulations comprising lipid-regulating agents
US6465011B2 (en) 1999-05-29 2002-10-15 Abbott Laboratories Formulations comprising lipid-regulating agents
JP4618845B2 (ja) 1999-06-09 2011-01-26 杏林製薬株式会社 ヒトペルオキシゾーム増殖薬活性化受容体(PPAR)αアゴニストとしての置換フェニルプロピオン酸誘導体
US6372251B2 (en) 1999-06-11 2002-04-16 Abbott Laboratories Formulations comprising lipid-regulating agents
GB9913782D0 (en) 1999-06-14 1999-08-11 Smithkline Beecham Plc Novel compounds
JP2003502370A (ja) 1999-06-18 2003-01-21 メルク エンド カムパニー インコーポレーテッド アリールチアゾリジンジオン誘導体およびアリールオキサゾリジンジオン誘導体
US6207699B1 (en) 1999-06-18 2001-03-27 Richard Brian Rothman Pharmaceutical combinations for treating obesity and food craving
DE60029446T2 (de) 1999-06-18 2007-02-08 Merck & Co., Inc. Arylthiazolidindione und aryloxazolidindion-derivate
GB9914977D0 (en) 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
HK1043369B (en) 1999-06-30 2014-06-13 日本烟草产业株式会社 Compounds for the modulation of ppar-gamma activity
CA2379948C (en) 1999-08-03 2008-03-25 Lilly Icos Llc Beta-carboline pharmaceutical compositions
EP1078632A1 (en) 1999-08-16 2001-02-28 Sanofi-Synthelabo Use of monoamine oxydase inhibitors for the manufacture of drugs intended for the treatment of obesity
GB9919413D0 (en) 1999-08-18 1999-10-20 Zeneca Ltd Chemical compounds
GB9919411D0 (en) 1999-08-18 1999-10-20 Zeneca Ltd Chemical compounds
WO2001014349A1 (en) 1999-08-23 2001-03-01 Kyorin Pharmaceutical Co., Ltd. Substituted benzylthiazolidine-2,4-dione derivatives
DE60020246T2 (de) 1999-08-23 2006-01-19 Kyorin Pharmaceutical Co., Ltd. Substituierte benzylthiazolidin-2,4-dion derivate
AU778721B2 (en) 1999-08-23 2004-12-16 Kyorin Pharmaceutical Co. Ltd. Substituted benzylthiazolidine-2,4-dione derivatives
DK1206457T3 (da) 1999-08-27 2004-02-16 Lilly Co Eli Biaryl-oxa(thia)zolderivater og deres anvendelse som modulatorer PPAP'ER
JP2003508453A (ja) 1999-08-31 2003-03-04 ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド アテローム性動脈硬化疾患の予防における診断的ツールとしての全身性炎症マーカー
AU7115300A (en) 1999-09-08 2001-04-10 Glaxo Group Limited Oxazole ppar antagonists
JP2004500037A (ja) 1999-09-08 2004-01-08 ジェネンテック・インコーポレーテッド 繊維芽細胞成長因子−19(fgf−19)核酸及びポリペプチド並びに肥満の治療のための利用の方法
US6174665B1 (en) 1999-09-10 2001-01-16 Biex, Inc. Hormone replacement therapy monitoring
HUP0202731A3 (en) 1999-09-17 2003-10-28 Kyorin Seiyaku Kk O-anisamide derivatives, process for their preparation and pharmaceutical compositions containing them
WO2001021259A2 (en) 1999-09-21 2001-03-29 Emory University Use and compositions for treating platelet-related disorders using anagrelide
WO2001021647A2 (en) 1999-09-22 2001-03-29 Genset Methods of screening for compounds that modulate the lsr-leptin interaction and their use in the prevention and treatment of obesity-related diseases
DE69923718T2 (de) 1999-09-24 2006-01-12 Kyorin Pharmaceutical Co., Ltd. Ppar-alpha und ppar-gamma-hemmer
WO2001022962A1 (en) 1999-09-30 2001-04-05 Merck & Co., Inc. Anti-hypercholesterolemic drug combination
AU2833701A (en) 1999-09-30 2001-05-10 Shell Internationale Research Maatschappij B.V. Adducts of glycidylesters of alpha, alpha-branched carboxylic acids and carboxylic acids and poly(ortho ester) as intermediate for their preparation
US6369098B1 (en) 1999-10-05 2002-04-09 Bethesda Pharmaceuticals, Inc. Dithiolane derivatives
AU1215701A (en) 1999-10-22 2001-05-08 Merck & Co., Inc. Pharmaceuticals for treating obesity
JP2003523948A (ja) 1999-11-04 2003-08-12 アンドルクス コーポレーション アミロイドβ前駆体障害の治療法
TWI271192B (en) 1999-11-11 2007-01-21 Kyorin Pharmaceutical Co Ltd Solid formulation for oral administration
CA2388807C (en) 1999-11-12 2013-08-06 Matthew C. Coffey Viruses for the treatment of cellular proliferative disorders
RU2256661C2 (ru) 1999-12-03 2005-07-20 Киото Фармасьютикал Индастриз, Лтд. Производные тетрагидроизохинолина и их соли и фармацевтическая композиция на их основе
DK1175220T3 (da) 1999-12-08 2005-08-29 Pharmacia Corp Nanopartikulære eplerenonkompositioner
WO2001045676A2 (en) 1999-12-20 2001-06-28 Schering Corporation Extended release oral dosage composition
US6248359B1 (en) 2000-01-05 2001-06-19 Laboratorios Phoenix U.S.A., Inc. Multi-tablet oxybutynin system for treating incontinence
WO2001056579A1 (en) 2000-02-04 2001-08-09 Esperion Therapeutics Inc. Methods for treating alzheimer's disease
WO2001060807A1 (en) 2000-02-18 2001-08-23 Merck & Co. Inc. Aryloxyacetic acids for diabetes and lipid disorders
NZ520024A (en) 2000-02-29 2005-03-24 Bristol Myers Squibb Co Low dose entecavir formulation and usein treating hepatitis B virus infection
WO2001076632A1 (en) 2000-04-10 2001-10-18 Wald Nicholas J Formulation for the prevention of cardiovascular disease
US6316029B1 (en) 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
US20020013334A1 (en) 2000-06-15 2002-01-31 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
US6191117B1 (en) 2000-07-10 2001-02-20 Walter E. Kozachuk Methods of producing weight loss and treatment of obesity
ATE362468T1 (de) 2000-07-25 2007-06-15 Merck & Co Inc N-substituierte indole mit anwendung in der behandlung von diabetes
US20020132855A1 (en) * 2000-08-03 2002-09-19 Nelson Edward B. Use of acetaminophen to prevent and treat arteriosclerosis
DE10042447A1 (de) * 2000-08-29 2002-03-28 Aventis Pharma Gmbh Protein aus dem Darm von Wirbeltieren, welches Cholesterin absorbiert, sowie Verwendung dieses Proteins zur Identifizierung von Inhibitoren des intestinalen Cholesterintransports
JP2004513090A (ja) * 2000-09-27 2004-04-30 メルク エンド カムパニー インコーポレーテッド 糖尿病及び脂質異常症の治療のためのベンゾピランカルボン酸誘導体
HUP0302269A3 (en) 2000-12-20 2009-08-28 Schering Corp Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
PL362379A1 (en) * 2000-12-21 2004-10-18 Aventis Pharma Deutschland Gmbh Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism
EE200300238A (et) * 2000-12-21 2003-08-15 Aventis Pharma Deutschland Gmbh Difenüülasetidinooni derivaadid, nende kasutamine, ravim ja selle valmistamismeetod
IL156552A0 (en) * 2000-12-21 2004-01-04 Aventis Pharma Gmbh Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
AR034204A1 (es) 2001-01-26 2004-02-04 Schering Corp Composiciones y combinaciones de acido nicotinico y derivados del mismo con inhibidor(es) de la absorcion de los esteroles, y el uso de los mismos para preparar medicamentos para el tratamiento para indicaciones vasculares
NZ526532A (en) 2001-01-26 2005-01-28 Schering Corp The use of substituted azetidinone compounds for the treatment of sitosterolemia
DK1363668T3 (da) 2001-01-26 2007-11-05 Schering Corp Kombinationer af galdesyrekompleksdanner(e) og sterolabsorptionsinhibitor(er) og behandling af vaskulære indikationer
US20030069221A1 (en) 2001-01-26 2003-04-10 Schering Corporation Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions
SI1413331T1 (sl) 2001-01-26 2008-02-29 Schering Corp Kombinacije fenofibrata peroksisomskega proliferator aktivirajocega receptorja (PPAR) z ezetimib zaviralcem absorpcije sterola za vaskularne indikacije
CN1658903A (zh) 2001-01-26 2005-08-24 先灵公司 用于治疗血管性疾病的固醇吸收抑制剂与血液调节剂的组合
US7091230B2 (en) * 2001-02-09 2006-08-15 Merck & Co., Inc. 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders
DE10106787A1 (de) 2001-02-12 2002-08-22 Nanogate Gmbh Wasserfrei hydrolisierte Sol-Gel-Systeme
CA2438492A1 (en) 2001-02-15 2002-08-22 Pfizer Products Inc. Proliferative activator receptor (ppar) compounds
MXPA03007284A (es) 2001-02-15 2003-12-04 Pfizer Prod Inc Agonistas de receptor activador del proliferador de peroxisomas.
JP2004523569A (ja) * 2001-03-08 2004-08-05 メルク エンド カムパニー インコーポレーテッド 抗高血圧薬とコレステロール吸収阻害薬の併用療法
US7348334B2 (en) * 2001-04-09 2008-03-25 Dr. Reddy's Laboratories Limited Monocyclic derivatives of aryl alkanoic acids and their use in medicine: process for their preparation and pharmaceutical compositions containing them
WO2002081454A1 (en) * 2001-04-09 2002-10-17 Dr. Reddy's Laboratories Ltd. Derivatives of aryl acids, their use in medicine, process for their preparation and pharmaceutical compositions containing them
AR038956A1 (es) 2001-05-25 2005-02-02 Schering Corp Uso de un compuesto que regula la produccion o niveles de peptidos beta amiloides para la manufactura de un medicamento para tratar la enfermedad de alzheimer y/o para regular dichos niveles de peptidos amiloides beta en un sujeto
EP1420826A2 (de) 2001-08-22 2004-05-26 Aventis Pharma Deutschland GmbH Kombinationspräparate von arylsubstituierten propanolaminderivaten mit weiteren wirkstoffen und deren verwendung
RS11104A (sr) 2001-08-22 2006-12-15 Sanofi Aventis Deutschland Gmbh. Kombinovani preparati derivata 1,4-benzotiepin-1,1-dioksida sa drugim aktivnim supstancama i njihova primena
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
WO2003026643A2 (en) 2001-09-21 2003-04-03 Schering Corporation Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
BR0212907A (pt) 2001-09-21 2004-10-13 Schering Corp Métodos para tratamento ou prevenção de inflamação vascular usando inibidor(es) da absorção de esteróis
US20030119808A1 (en) 2001-09-21 2003-06-26 Schering Corporation Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
WO2003039542A1 (en) 2001-10-17 2003-05-15 Merck & Co. Inc. Combination therapy for treating alzheimer's disease
US20050123580A1 (en) 2002-02-28 2005-06-09 Burris Thomas P. Method of treating atherosclerosis and hypercholesterolemia
WO2003088962A1 (en) 2002-04-16 2003-10-30 Merck & Co., Inc. Combination therapy using a ppar alpha/gamma agonist

Also Published As

Publication number Publication date
NO331512B1 (no) 2012-01-16
DE60222773T2 (de) 2008-07-17
ATE374641T1 (de) 2007-10-15
EP1413331B1 (en) 2007-10-03
HUP0303915A2 (hu) 2004-03-01
IL156445A (en) 2010-11-30
RS51449B (sr) 2011-04-30
US20080058306A1 (en) 2008-03-06
PT1353696E (pt) 2007-02-28
CZ2010307A3 (enExample) 2004-01-14
EP1353696B1 (en) 2006-12-20
US20020192203A1 (en) 2002-12-19
CN100509058C (zh) 2009-07-08
AU2002247019C1 (en) 2017-05-11
DE60222773D1 (de) 2007-11-15
MXPA03006725A (es) 2003-10-24
NO20033355D0 (no) 2003-07-25
CN1646165A (zh) 2005-07-27
EP1413331A3 (en) 2004-06-30
AU2002247019B2 (en) 2006-08-03
KR100596257B1 (ko) 2006-07-03
SK287988B6 (sk) 2012-09-03
DK1413331T3 (da) 2007-12-10
DE60216890D1 (de) 2007-02-01
CA2562982A1 (en) 2002-08-01
CA2562982C (en) 2011-03-15
PL208110B1 (pl) 2011-03-31
SK288217B6 (sk) 2014-08-05
KR20040025887A (ko) 2004-03-26
ECSP11004702A (es) 2011-03-31
SK9482003A3 (en) 2003-12-02
RS20100015A (sr) 2010-12-31
JP2012087149A (ja) 2012-05-10
DE60216890T2 (de) 2007-08-30
IL156445A0 (en) 2004-01-04
AR064012A2 (es) 2009-03-04
ATE348649T1 (de) 2007-01-15
JP2004521893A (ja) 2004-07-22
CZ309209B6 (cs) 2022-05-25
ES2274013T3 (es) 2007-05-16
US7030106B2 (en) 2006-04-18
CY1108000T1 (el) 2013-09-04
TWI337083B (en) 2011-02-11
NZ525921A (en) 2005-06-24
DK1353696T3 (da) 2007-04-10
ZA200305693B (en) 2005-04-26
HU230253B1 (hu) 2015-11-30
EP1353696A2 (en) 2003-10-22
JP4777602B2 (ja) 2011-09-21
WO2002058732B1 (en) 2003-09-12
CL2004001174A1 (es) 2005-05-06
US20020151536A1 (en) 2002-10-17
CZ301871B6 (cs) 2010-07-14
SI1413331T1 (sl) 2008-02-29
PL368653A1 (en) 2005-04-04
US7612058B2 (en) 2009-11-03
JP2007211031A (ja) 2007-08-23
RU2356550C2 (ru) 2009-05-27
US20060199793A1 (en) 2006-09-07
JP2008088184A (ja) 2008-04-17
ES2290562T3 (es) 2008-02-16
EP1413331A2 (en) 2004-04-28
CZ20032030A3 (cs) 2004-01-14
NO20033355L (no) 2003-07-25
HK1063607A1 (en) 2005-01-07
WO2002058732A3 (en) 2003-07-03
US20050153952A1 (en) 2005-07-14
YU58603A (sh) 2006-05-25
CA2434682A1 (en) 2002-08-01
RU2008144912A (ru) 2010-05-20
AR033855A1 (es) 2004-01-07
JP4937836B2 (ja) 2012-05-23
BR0206654A (pt) 2004-02-25
CY1107045T1 (el) 2012-09-26
HK1056696A1 (en) 2004-02-27
PT1413331E (pt) 2007-12-18
CA2434682C (en) 2008-11-18
IL191417A (en) 2011-12-29
SI1353696T1 (sl) 2007-04-30
MEP27808A (en) 2010-10-10
WO2002058732A2 (en) 2002-08-01
HUP0303915A3 (en) 2012-12-28
RU2003126184A (ru) 2005-03-10

Similar Documents

Publication Publication Date Title
CA2562982C (en) Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
AU2002247019B9 (en) Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
CA2460340C (en) Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors
US20030053981A1 (en) Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications
AU2002247019A1 (en) Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
US20020183305A1 (en) Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications
CA2434430A1 (en) The use of substituted azetidinone compounds for the treatment of sitosterolemia
CA2460344A1 (en) Methods for treating or preventing vascular inflammation using sterol absorption inhibitor(s)
AU2002335770A1 (en) Methods for treating or preventing vascular inflammation using sterol absorption inhibitor(s)
AU2008201609B2 (en) Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitors(s) and treatments for vascular indications
AU2006202618B9 (en) Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
AU2007201970B2 (en) Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
EP1911462A2 (en) Compositions comprising a sterol absorption inhibitor
HK1115810A (en) Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
HK1117416A (en) Compositions comprising a sterol absorption inhibitor
HK1093025A (en) Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications
NZ539190A (en) Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
EP1864680A2 (en) Combinations of peroxisome proliferator-activated receptor (PPAR) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
HK1064950B (en) Methods for treating or preventing vascular inflammation using sterol absorption inhibitor(s)

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued